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U reteral stents are widely used for the manage-ment of upper urinary tract obstruction for var-
ious etiologies,  and approx.  80% of patients with an 
indwelling ureteral stent suffer from stent-related symp-
toms (SRSs),  including lower urinary tract symptoms 
(LUTS),  hematuria,  body pain,  and poor quality of life 
(QoL) [1 , 2].  The most effective approach to manage 
SRSs is to prevent the need for a stent initially; how-
ever,  after a ureterorenoscopic lithotripsy (URSL) for 
upper urinary calculi,  a majority of the patients require 
ureteral stent placement for the alleviation of an 
obstruction by a stent’s maintenance of the ureteral 
lumen’s patency.
LUTS,  bladder discomfort,  and hematuria are pre-
sumed to arise from a mechanical irritation of the blad-
der neck and/or trigone induced by an indwelling stent,  
whereas flank pain is associated with vesicoureteral 
reflux [3].  To address these problems,  several studies 
aimed at improving stent designs and compositions 
have been conducted [4-6].  Although many studies 
have indicated that alpha-1 blockers,  antimuscarinics,  
and other agents can relieve the discomfort and prob-
lems related to an indwelling stent and ultimately 
improve the patients’ QoL [7-24],  conflicting results 
have been obtained by studies that compared the effi-
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To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling uret-
eral stent after ureterorenoscopic lithotripsy.  This was a prospective follow-up study of 76 patients with 
stent-related symptoms (SRSs).  Patients with upper urinary calculi who were pre-stented for > 2 weeks before 
lithotripsy were examined for the presence of SRSs by tests including the International Prostate Symptom Score 
(IPSS),  OAB Symptom Score (OABSS),  and urinary bother and pain measured by a Visual Analogue Scale 
(VAS) before lithotripsy.  Mirabegron (50 mg/day) was prescribed post-lithotripsy for 2 weeks.  SRSs were 
assessed at the time of stent removal.  The IPSS scores improved significantly from 16.2 to 14.3 (p< 0.001) and 
the IPSS-QoL scores decreased significantly from 5.0 to 4.6 (p= 0.012).  The OABSS scores improved signifi-
cantly from 7.7 to 6.8 (p= 0.006),  and the urinary urgency scores (OABSS-Q3) decreased significantly from 3.24 
to 2.68 (p< 0.001).  The number of nocturia episodes decreased significantly from 2.5 to 2.2 (p= 0.045).  Urinary 
bother and pain assessed by the VAS declined from 4.2 and 3.1 to 3.8 (p= 0.15) and 2.5 (p= 0.075),  respectively.  
Mirabegron significantly improved SRSs and the number of nocturia episodes due to a ureteral stent.
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cacy of monotherapy with that of combination therapy 
using both alpha-1 blockers and antimuscarinic agents 
[17 , 18].
To date,  only one study has concentrated on the 
β3-adrenoceptor agonist mirabegron as part of efforts to 
address SRSs,  and in that study a significant improve-
ment of urinary symptoms was not achieved with mira-
begron treatment [25].  Mirabegron has demonstrated 
efficacy and tolerability for patients with overactive 
bladder (OAB) symptoms [26-28].  We conducted the 
present study to investigate the efficacy of mirabegron 
in patients with an indwelling ureteral stent after URSL.
Patients and Methods
Patients. This was a single-center,  prospective 
follow-up study that targeted patients with SRSs.  We 
studied patients who underwent a URSL with an 
indwelling ureteral stent at Abiko Toho Hospital (Chiba,  
Japan) between November 2016 and March 2018.  The 
study was approved by the Institutional Review Board of 
our hospital (Approval no. 201601).  Written informed 
consent was obtained from all of the study participants.
The inclusion criteria were as follows: (1) patients 
with upper urinary calculi who received a 6-Fr ureteral 
stent > 2 weeks before their URSL,  (2) those with OAB 
symptoms due to an indwelling ureteral stent,  (3) those 
with a stone-free status attained after URSL,  (4) those 
who provided consent for 2-week mirabegron adminis-
tration,  and (5) those who were evaluated for SRSs 
before the removal of their stent.
After the URSL of each patient,  a stent of the same 
size as that inserted at pre-stenting was inserted.  After 
both insertions,  kidney-ureter-bladder (KUB) X-ray 
plain film images were taken to ensure that the stent was 
at an appropriate position,  because an over-midline 
positioning of the distal end of the stent might worsen 
LUTS [29 , 30].  The details of our URSL procedures 
have been described [31 , 32].
The exclusion criteria were as follows: patients with 
(1) lower ureteral calculi; (2) pre-existing OAB,  inter-
stitial cystitis,  chronic prostatitis,  chronic pelvic pain 
syndrome,  or active urinary tract infection (UTI); (3) 
those with stent dislodgement; (4) those with a con-
comitant use of an adrenergic alpha-1 receptor antago-
nists,  antimuscarinic agent,  or analgesic; and those (5) 
with a history of urinary tract surgery,  (6) drug allergy,  
or (7) a history of neurogenic bladder,  neurologic and 
psychiatric disease(s),  or dementia.
Assessment of the patients’ symptoms and out-
comes. Based on the patient’s OAB Symptom Score 
(OABSS) [33],  the diagnosis of OAB was defined as a 
Urinary Urgency Score (OABSS-Q3) ≥ 2 plus an OABSS 
total score ≥ 3.  All patients were investigated for the 
absence of OAB before the first ureteral stent placement 
(pre-stenting).  Pre-stenting was performed > 2 weeks 
before the URSL.  The patients completed a form that 
included the International Prostate Symptom Score 
(IPSS),  the IPSS-QoL score,  the OABSS,  and a visual 
analog scale (VAS) that was used to assess the patient’s 
sense of urinary bother and pain before URSL.
For the patients with OAB due to a ureteral stent,  
mirabegron (50 mg/day) was prescribed the day after 
the URSL and continued until the stent removal.  
Patients were discharged on day 2 or 3 after their URSL 
surgery.  Approximately 2 weeks after the URSL surgery,  
each patient returned to our hospital and was inter-
viewed by a physician for the identification of any side 
effects; the patient underwent a urinalysis to check for 
a UTI; and he or she was checked for stent dislodge-
ment and the presence/absence of visible fragments on 
KUB X-ray films,  any symptoms after mirabegron 
administration.  The stent’s removal was then con-
ducted.  The flowchart of this study is given as Fig. 1.  
We analyzed the collected data of the patients by using a 
paired t-test.  Probability values < 0.05 were accepted as 
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2 weeks
Fig. 1　 Study flowchart.
significant.
Results
Of the 98 eligible patients,  22 patients without SRSs 
were not prescribed mirabegron after their URSL,  and 
the final sample size was thus 76.  Table 1 summarizes 
the patients’ demographics.  None of the patients had a 
history of urinary tract surgery or concomitant use of 
other similar drugs or any other comorbidity that could 
have affected the assessment of SRSs.  No stents were 
dislodged.
The changes in the patients’ urinary symptom scores 
are summarized in Table 2.  The total IPSS score was 
16.3 without mirabegron,  and this score was signifi-
cantly reduced to 14.3 after mirabegron treatment 
(50 mg/day) (p < 0.001).  The patients’ IPSS voiding 
score and storage symptom score fell from 7.2 and 9.1 
to 6.5 (p = 0.074) and 7.7 (p < 0.001),  respectively.  The 
IPSS-QoL values decreased from 5.0 to 4.6 (p = 0.012).  
The total OABSS value fell from 7.7 before surgery to 
6.8 after the mirabegron treatment (p = 0.006).  The uri-
nary urgency score (OABSS-Q3) decreased significantly 
from 3.24 to 2.68 (p < 0.001),  but the patients’ urgency 
incontinence score (OABSS-Q4) did not change signifi-
cantly (from 1.08 to 0.95,  p = 0.4).  The change in the 
patients’ urinary bother score as revealed by the VAS 
decreased from 4.2 to 3.8,  which was not significant 
(p = 0.15).  The pain score evaluated by the VAS dropped 
from 3.1 before the mirabegron treatment to 2.5 at the 
time point of stent removal; however,  this change was 
not significant (p = 0.075).
The number of nocturia episodes per night fell by 
one episode in 37% of the patients,  whereas it did not 
change in another 36% of the patients.  The number of 
nocturia episodes fell significantly from 2.5 to 2.2 after 
mirabegron treatment (p = 0.045).  None of the patients 
discontinued their mirabegron treatment due to side 
effects.
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Table 1　 Demographics of the patients
Overall (n＝76)
Factors Mean±SD Rate Range
Gender Male 48 63%
Female 28 37%
Age (years) 59.9±11.7 31-82
BMI 24.0±4.3 13.4-43.3
ASA score class 1 43 57%
class 2 30 39%
class 3 3 4%
Comorbidity Diabetes mellitus 15 20%
Hypertension 25 33%
Hyperlipidemia 12 16%
Hyperuricemia 4 5%
Stone location Calyx 9 12%
Renal pelvis 8 10%
UPJ 9 12%
Upper ureter 38 50%
Middle ureter 12 16%
Laterality Right 36 47%
Left 40 53%
Stone diameter (mm) 13.3±8.2 3.6-31
BMI,  body mass index; UPJ,  ureteropelvic junction.
Discussion
The results of our analyses revealed a significant 
improvement of SRSs after mirabegron treatment.  At 
present,  the most useful measure for the evaluation of 
SRSs is the ureteral stent symptom questionnaire 
(USSQ) established by Joshi [34]; however,  the USSQ 
was not available in Japanese during the study period.  
We therefore used the OABSS,  IPSS,  and VAS to eval-
uate the patients’ urinary bother and pain in daily life.
Of the 98 eligible patients,  76 patients (78%) experi-
enced SRSs,  whereas the other 22 did not.  The location 
of calculi was confined to the upper ureter,  ureteropel-
vic junction,  renal pelvis,  and calyces.  We excluded 
patients with lower ureteral calculi because these calculi 
can cause LUTS and complicate the evaluations of 
symptoms.
The PolarisTM Ultra stent (Boston Scientific,  
Marlborough,  MA,  USA) is made of polyolefin with 
hydrophilic coating.  The distal end of this stent is called 
the NautilusTM Coil,  which is convoluted inside the 
stent in order to reduce stimuli against the bladder 
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Table 2　 Changes in urinary parameters
Mirabegron (－) Mirabegron (＋) p value
IPSS total score 16.3±7.1 14.3±7.5 ＜0.001
　IPSS voiding score 7.2±5.0 6.5±5.0 0.074
　IPSS storage score 9.1±3.3 7.7±3.6 ＜0.001
IPSS-QoL 5.0±1.2 4.6±1.5 0.012
OABSS total score 7.7±3.0 6.8±3.3 0.006
　Q3 (urgency score) 3.24±1.3 2.68±1.6 ＜0.001
　Q4 (urgency incontinence score) 1.08±1.5 0.95±1.5 0.4
VAS urinary bother 4.2±2.7 3.8±2.6 0.15
VAS pain 3.1±2.5 2.5±2.4 0.075
Nocturia 2.5±1.3 2.2±1.4 0.045
IPSS,  international prostate symptom score; OABSS,  overactive bladder symptom score; VAS,  visual analogue scale.
Table 3　 Studies of the outcomes of medical therapy for stent-related symptoms
Author
Reference
number
Reported
year
Number of
patients
Drug used Opinion/Conclusion
Deliveliotis 8 2006 100 alfzocin Effective
Damiano 9 2008 75 tamsulosin Effective
Beddingfield 10 2009 66 alfzocin Effective
Valiere 11 2011 79 tamsulosin Not effective
Lim 12 2011 168 tamsulosin,  solifenacin Combination was better.
Shalaby 13 2013 338 terazosin,  tolterodine Combination was better.
Tehranchi 14 2013 94 terazosin,  tolterodine Combination was better.
Lee 15 2013 140 solifenasin Effective
Dellis 16 2014 150 alfzocin,  tamsulosin The both was effective.
Park 17 2015 81 tamsulosin,  solifenacin Neither combination nor monotherapy was effective.
Sivalingam 18 2016 80 tamsulosin,  tolterodine Add-on of tolterodine was not effective.
El-Nahas 19 2016 131 tamsulosin,  solifenacin Solifenacin was better than tamsulosin.
Liu 20 2016 100 solifenacin,  tamsulosin Combination was better within 4 days.
Ragab 21 2017 500 pregabalin,  solifenacin Pregabalin eased pain,  solifenacin improved LUTS.
Lee 22 2017 71 belladonna and opium suppository Effective
Dellis 23 2017 260 solifenacin,  tamsulosin The both was effective.
Maldonado 24 2017 51 tamsulosin,  oxybutynin Combination was better.
Tae 25 2018 96 mirabegron Mirabegron eased pain.
LUTS,  lower urinray tract symptoms.
mucosa.  In the present study,  78% of the patients expe-
rienced SRSs; this may be attributed to the rigidness of 
the Polaris Ultra stent design to prevent SRSs.  
Kawahara reported the usefulness of a loop-type stent to 
reduce SRSs [35].  The application of stents that are 
made of softer or thinner material might therefore have 
produced different results in this study.
Irani et al.  reported changes in patients’ tolerance to 
SRSs with time [36].  They assessed urinary symptoms 
at 24 h and again 1 week after placement,  and on the 
day before stent removal.  Although some symptoms 
(e.g.,  dysuria and hematuria) improved significantly 
with time,  the patients’ general tolerance to SRSs 
remained unchanged.  Some of the irritative symptoms 
observed a few days after the stent placement were sug-
gested to be caused by the effects of instrumentation.  In 
the present study,  symptom assessments were per-
formed > 2 weeks after the initial stent placement and a 
further 2 weeks after the URSL.  Therefore,  the symp-
tom improvement with time seemed to be slight 
between the primary and the secondary assessments,  
and the amelioration of the patients’ urinary symptom 
scores approximately reflected the symptom relief by 
mirabegron treatment.
The prior randomized controlled trials for medical 
therapy against SRSs are summarized in Table 3.  The 
majority of the previous studies reported the usefulness 
of antimuscarinics and alpha-1 blockers for SRSs 
[8-10 , 15 , 16],  and several research groups have indi-
cated the efficacy of combination therapy [12-14 , 20 ,  
23 , 24] and analgesics [21 , 22].  Tae et al.  demonstrated 
that compared to no treatment,  mirabegron has the 
potential to reduce SRSs [25].  In their study,  the post-
operative USSQ body pain score and the overall pain 
score were lower in the mirabegron group compared to 
the no-treatment group.  The USSQ urinary symptom 
scores,  IPSS total scores,  and QoL scores were lower in 
the mirabegron group,  but the differences were not sig-
nificant [25]; this might be due to the study’s small 
sample size.
In the present study,  mirabegron significantly 
reduced the total IPSS,  OABSS,  and IPSS storage 
symptom scores for patients with an indwelling ureteral 
stent.  Urinary bother,  as measured by the VAS,  was not 
significantly improved (p = 0.15),  but the patients’ pain 
became less severe (although not significantly so;  
p = 0.075).  The number of the patients’ nocturia epi-
sodes per night decreased significantly from 2.5 to 2.2 
(p = 0.045).  Our findings thus indicated that mirabe-
gron improves LUTS,  reduces the number of nocturia 
episodes,  and has the potential to alleviate pain due to 
an indwelling ureteral stent.
This study has some limitations.  It was not a multi- 
center or placebo-controlled study.  Other limitations 
are the study’s small sample size (n = 76),  the evaluation 
of SRSs without the use of the USSQ,  the lack of an 
evaluation of the patients’ sexual activity,  the potential 
of the aggravation of LUTS due to instrumentation,  and 
the lack of a urodynamic study.
In conclusion,  mirabegron treatment for SRSs sig-
nificantly decreased the patients’ IPSS,  IPSS-QoL,  and 
OABSS scores and the number of nocturia episodes per 
night.  Mirabegron alleviated urinary symptoms due to 
the patients’ ureteral stents.  Thus,  mirabegron is a safe 
drug and is effective for improving stent-related symp-
toms.
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